Phase Z of A-Z Trial

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

Phase Z of A-Z Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Phase Z of A-Z Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Phase Z of A-Z Trial

CDC on Phase Z of A-Z Trial

Phase Z of A-Z Trial in the news

Blogs on Phase Z of A-Z Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for Phase Z of A-Z Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

To compare early initiation of an intensive statin regimen with delayed initiation of a less intensive regimen in patients with ACS.

Methods

The Z phase of A-Z trial was a multicentered, randomized, double blinded trial which enrolled 4497 patients with acute coronary syndrome who had an initial total cholesterol level ≤250 mg/dL. All the patients were randomized to treatment with either 40 mg/d of simvastatin for 1 month followed by 80 mg/d thereafter or placebo for 4 months followed by 20 mg/d of simvastatin. All the patients were followed-up for 6 months to 24 months. Primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, readmission for ACS, and stroke.

Results

  • In the less intense treatment group, median LDL-C level achieved while taking placebo was 122 mg/dL at 1 month and was 77 mg/dL at 8 months while taking 20 mg/d of simvastatin. Corresponding values in the simvastatin only group were 68 mg/dL at 1 month while taking 40 mg/d of simvastatin and 63 mg/dL at 8 months while taking 80 mg/d of simvastatin.
  • Primary endpoint was reached in 16.7% in the placebo plus simvastatin group compared with 14.4% in the simvastatin only group.
  • Cardiovascular death occurred in 5.4% and 4.1% of the patients in the 2 groups but no differences were observed in other individual components of the primary end point.

Conclusion

The pre-specified end point was not achieved by the trial. However the early initiation of an aggressive simvastatin regimen, in patients with ACS, resulted in a favorable trend toward reduction of major cardiovascular events.[1][2]

References

  1. de Lemos JA, Blazing MA, Wiviott SD; et al. (2004). "Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial". JAMA : the Journal of the American Medical Association. 292 (11): 1307–16. doi:10.1001/jama.292.11.1307. PMID 15337732. Unknown parameter |month= ignored (help)
  2. Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E (2001). "The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy". American Heart Journal. 142 (2): 211–7. doi:10.1067/mhj.2001.116959. PMID 11479456. Unknown parameter |month= ignored (help)